- Home
- EVOK vs CERO Comparison
EVOK vs CERO Comparison
Compare EVOK & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- CERO
- Stock Information
- Founded
- EVOK 2007
- CERO 2017
- Country
- EVOK United States
- CERO United States
- Employees
- EVOK N/A
- CERO N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- EVOK Health Care
- CERO
- Exchange
- EVOK Nasdaq
- CERO Nasdaq
- Market Cap
- EVOK 7.7M
- CERO 3.5M
- IPO Year
- EVOK 2013
- CERO N/A
- Fundamental
- Price
- EVOK $3.85
- CERO $7.00
- Analyst Decision
- EVOK
- CERO Strong Buy
- Analyst Count
- EVOK 0
- CERO 2
- Target Price
- EVOK N/A
- CERO $45.00
- AVG Volume (30 Days)
- EVOK 7.2M
- CERO 90.4K
- Earning Date
- EVOK 08-12-2025
- CERO 08-13-2025
- Dividend Yield
- EVOK N/A
- CERO N/A
- EPS Growth
- EVOK N/A
- CERO N/A
- EPS
- EVOK N/A
- CERO N/A
- Revenue
- EVOK $11,594,083.00
- CERO N/A
- Revenue This Year
- EVOK $57.82
- CERO N/A
- Revenue Next Year
- EVOK $59.12
- CERO N/A
- P/E Ratio
- EVOK N/A
- CERO N/A
- Revenue Growth
- EVOK 89.89
- CERO N/A
- 52 Week Low
- EVOK $1.94
- CERO $6.71
- 52 Week High
- EVOK $12.32
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- EVOK 46.17
- CERO 38.07
- Support Level
- EVOK $4.26
- CERO $7.27
- Resistance Level
- EVOK $4.70
- CERO $8.83
- Average True Range (ATR)
- EVOK 0.43
- CERO 0.45
- MACD
- EVOK -0.15
- CERO -0.09
- Stochastic Oscillator
- EVOK 4.80
- CERO 6.71
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.